ONCAlert | Upfront Therapy for mRCC

Final KEYNOTE-048 Results With Frontline Pembrolizumab in Recurrent/Metastatic HNSCC

Danny Rischin, MD
Published Online: 12:57 AM, Mon June 3, 2019

Danny Rischin, MD, director, Division of Cancer Medicine, head, Department of Medical Oncology, Peter MacCallum Cancer Centre, discusses results from the protocol-specified final analysis of the phase III KEYNOTE-048 trial of pembrolizumab (Keytruda) as frontline therapy for recurrent/metastatic head and neck squamous cell carcinoma.

Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.